In the BioHarmony Drug Report Database
Scopolamine
Transderm Scop (scopolamine) is a small molecule pharmaceutical. Scopolamine was first approved as Transderm Scop on 1982-01-01. It is used to treat colonic diseases, diverticulitis, dysentery, facial paralysis, and iridocyclitis amongst others in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M1 and muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M4, and muscarinic acetylcholine receptor M5.
Trade Name
|
Transderm Scop |
|---|---|
Common Name
|
scopolamine |
ChEMBL ID
|
CHEMBL569713 |
Indication
|
colonic diseases, diverticulitis, dysentery, facial paralysis, iridocyclitis, postencephalitic parkinson disease, vasomotor rhinitis |
Drug Class
|
antimuscarinic deliriant antiemetic amnestic |
Image (chem structure or protein)